Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dietary Intervention With Phytochemicals and Polyunsaturated Fatty Acids in Prostate Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00433797
Recruitment Status : Completed
First Posted : February 12, 2007
Last Update Posted : December 19, 2013
Sponsor:
Collaborators:
Oslo University Hospital
Norwegian Cancer Society
The Research Council of Norway
Information provided by (Responsible Party):
Rune Blomhoff, University of Oslo

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
We will study the effect of dietary intervention in patients with prostate cancer. Outcomes include serum PSA kinetics, as well as biomarkers of inflammation, antioxidant status, oxidative stress and oxidative damage in blood cells, plasma, urine and prostate tissues

Condition or disease Intervention/treatment Phase
Prostate Cancer Dietary Supplement: Prostate cancer, phytochemical and PUFA Phase 1 Phase 2

Detailed Description:

A total of 102 patients with localized prostate cancer will be included in the study. A the time of inclusion, the participants will be randomized to three groups.

The intervention groups includes; control group, tomato group and multi-diet group. The intervention period is three week and will be completed before prostatectomy or radiation therapy.

Biomarkers og inflammation includes: acute phase proteins, cytokines, chemokines and other inflammatory mediators. Biomarker of antioxidant status includes vitamin C, vitamin E, glutathione, carotenoids, total antioxidant capacity and total phenolics. Oxidative stress markers includes; malondialdehyde, isoprostanes, 8-hydroxy-deoxyguanosine, oxidized vitamin C, total lipidperoxides (d-ROM) and protein carbonyls.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Prostate Phytochemical & PUFA Intervention - a Phase I/II Study
Study Start Date : June 2007
Actual Primary Completion Date : March 2012
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: 1
Tomato
 Dietary Supplement: Prostate cancer, phytochemical and PUFA
Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.
Other Name: PFPI
Experimental: 2
Multi-diet
 Dietary Supplement: Prostate cancer, phytochemical and PUFA
Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.
Other Name: PFPI
Active Comparator: 3
Control
 Dietary Supplement: Prostate cancer, phytochemical and PUFA
Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.
Other Name: PFPI


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. serum prostate specific antigen [ Time Frame: Baseline, after intervention, follow-up ]

Secondary Outcome Measures :
  1. oxidative stress biomarkers in blood, tissue and urine [ Time Frame: Baseline, after intervention, follow-up ]
  2. antioxidant status biomarkers in blood, tissue and urine [ Time Frame: Baseline, after intervention, follow-up ]
  3. oxidative damage biomarkers in blood, tissue and urine [ Time Frame: Baseline, after intervention, follow-up ]
  4. inflammation biomarkers in blood, tissue and urine [ Time Frame: Baseline, after intervention, follow-up ]
  5. Apoptose markers in prostate tissue [ Time Frame: Baseline, after intervention, follow-up ]
  6. DNA microarrays in blood cells and prostate tissue [ Time Frame: Baseline, after intervention, follow-up ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adenoarcinoma (as confirmed by histology)
  • pN0/NXM0 (TNM/UICC 2002) and at least one negative prognosis factor for HDR-BT or low risk profile with the use of radical prostatectomy.
  • Serum PSA< 20 ng/mL, and Gleason score =>6 or T1c- T3a, prostate volume < 60mL
  • Performance status 0-1
  • Normal WBC and thromocytes, Hb >11g/dl

Exclusion Criteria:

  • No previous endocrine treatment
  • Life expectancy > 5 år
  • No possible co-morbidity (CVD, COPD, diabetes type I, vasculatory syndromes or inflammatory diseases that may affect quality of life and radiation therapy)
  • Urinary retention, incontinens or IPPS score <12
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00433797


Locations
Layout table for location information
Norway
Oslo Universuty Hospital, Radiumhospitalet and Aker
Oslo, Norway, 0310
Sponsors and Collaborators
University of Oslo
Oslo University Hospital
Norwegian Cancer Society
The Research Council of Norway
Investigators
Layout table for investigator information
Principal Investigator: Wolfgang Lilleby, MD Rikshospitalet-Radiumhospitalet, Oslo
Principal Investigator: Sigbjørn Smeland, MD, PhD. Rikshospitalet-Radiumhospitalet, Oslo
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Rune Blomhoff, Professor, University of Oslo
ClinicalTrials.gov Identifier: NCT00433797    
Other Study ID Numbers: PFPI
S-06187 (REK Sør) ( Other Identifier: REK Sør )
2006-18 (RRHF) ( Other Identifier: Oslo University Hospital )
First Posted: February 12, 2007    Key Record Dates
Last Update Posted: December 19, 2013
Last Verified: December 2013
Keywords provided by Rune Blomhoff, University of Oslo:
Prostate cancer
PSA
antioxidant
phytochemical
tomatoes
 PUFA
selenium
soy
pomegranate
grapes
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
 Neoplasms by Site
Neoplasms
Prostatic Diseases